New investor files pharma IPR as patent validity challenges look like being an increasing trend in 2016
Another investment group has filed an inter partes review (IPR) against a pharmaceutical patent, joining the small band of investors that have started to pose a significant challenge to leading drugmakers in the US. The IPR was filed just before…
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.